Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 07, 2021

SELL
$16.56 - $25.46 $8,180 - $12,577
-494 Closed
0 $0
Q4 2020

Jan 13, 2021

BUY
$15.77 - $19.03 $6,181 - $7,459
392 Added 384.31%
494 $8,000
Q3 2020

Nov 12, 2020

SELL
$16.59 - $24.79 $2,621 - $3,916
-158 Reduced 60.77%
102 $2,000
Q2 2020

Aug 13, 2020

SELL
$16.86 - $23.44 $52,839 - $73,460
-3,134 Reduced 92.34%
260 $6,000
Q1 2020

May 12, 2020

SELL
$14.47 - $27.96 $35,451 - $68,502
-2,450 Reduced 41.92%
3,394 $61,000
Q4 2019

Feb 07, 2020

BUY
$15.87 - $23.12 $92,379 - $134,581
5,821 Added 25308.7%
5,844 $126,000
Q3 2019

Nov 14, 2019

BUY
$16.91 - $36.27 $388 - $834
23 New
23 $0

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $154M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Sowell Financial Services LLC Portfolio

Follow Sowell Financial Services LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sowell Financial Services LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sowell Financial Services LLC with notifications on news.